Advertisement


Amy J. Davidoff, PhD, on Racial Disparities in Time to Cancer Treatment: The Effect of Medicaid Expansion

2019 ASCO Annual Meeting

Advertisement

Amy J. Davidoff, PhD, of Yale University School of Public Health, discusses study findings on how expanding access to Medicaid through the Affordable Care Act (ACA) reduced racial disparities among patients with advanced cancer. Before the ACA was implemented in 2014, black patients with cancer were less likely than white patients to receive timely treatment, but in states that did not adopt Medicaid expansion, racial disparities persist (Abstract LBA1).



Related Videos

Lung Cancer
Immunotherapy

Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes

Miriam Knoll, MD, of Hackensack University Medical Center, and Richard J. White, DO, of Allegheny Health Network, discuss improved overall survival among younger female patients with non–small cell lung cancer who have a lower comorbidity score, lower grade, private insurance, and treatment with intensity-modulated radiation therapy (Abstract 9024).

Breast Cancer

Rowan T. Chlebowski, MD, PhD, on Breast Cancer Incidence and Mortality: Results From the Women’s Health Initiative on the Effects of a Low-Fat Diet

Rowan T. Chlebowski, MD, PhD, of the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, discusses study findings from nearly 2 decades of data, which showed a 21% reduction in deaths from breast cancer among postmenopausal women who adhered to a low-fat diet (Abstract 520).

Lung Cancer

Taofeek Kunle Owonikoko, MD, PhD, on Small Cell Lung Cancer: Tremelimumab and Durvalumab With or Without Radiation

Taofeek Kunle Owonikoko, MD, PhD, of Emory University, discusses the findings of his phase II study, which assessed the efficacy of combined immune checkpoint inhibitors with or without radiation in relapsed small cell lung cancer (Abstract 8515).

Solid Tumors
Immunotherapy

Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations

Toni K. Choueiri, MD, and Sarah Abou Alaiwi, MD, both of Dana-Farber Cancer Institute, discuss the association of polybromo-associated BAF-type mutations with overall survival in patients with different solid tumors treated with checkpoint inhibitors (Abstract 103).

Kidney Cancer
Immunotherapy

Neeraj Agarwal, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: KEYNOTE-426 on First-Line Pembrolizumab Plus Axitinib vs Sunitinib

Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss phase III study findings on outcomes with combination therapy for intermediate/poor-risk and sarcomatoid subgroups of renal cell carcinoma (Abstract 4500).

 

Advertisement

Advertisement




Advertisement